Total Payments
$38,972
2021 Payments
$7,750
Companies
4
Transactions
27
Medicare Patients
227
Medicare Billing
$25,173
Payment Breakdown by Category
Consulting$36,505 (93.7%)
Travel$2,009 (5.2%)
Food & Beverage$258.65 (0.7%)
Education$198.99 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $36,505 | 5 | 93.7% |
| Travel and Lodging | $2,009 | 11 | 5.2% |
| Food and Beverage | $258.65 | 9 | 0.7% |
| Education | $198.99 | 2 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $21,916 | 14 | $0 (2020) |
| Shionogi Inc | $9,106 | 10 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,750 | 1 | $0 (2021) |
| Janssen Products, LP | $198.99 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2021 | $7,750 | 1 | Takeda Pharmaceuticals U.S.A., Inc. ($7,750) |
| 2020 | $10,580 | 2 | GlaxoSmithKline, LLC. ($10,580) |
| 2019 | $9,106 | 10 | Shionogi Inc ($9,106) |
| 2018 | $11,435 | 13 | GlaxoSmithKline, LLC. ($11,336) |
| 2017 | $99.99 | 1 | Janssen Products, LP ($99.99) |
All Payment Transactions
27 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/18/2021 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $7,750.00 | General |
| 12/22/2020 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $5,290.00 | General |
| 11/03/2020 | GlaxoSmithKline, LLC. | SHINGRIX (Biological) | Consulting Fee | Cash or cash equivalent | $5,290.00 | General |
| Category: VACCINES | ||||||
| 02/13/2019 | Shionogi Inc | Fetroja (Drug) | Consulting Fee | Cash or cash equivalent | $8,000.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 02/13/2019 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 02/13/2019 | Shionogi Inc | Fetroja (Drug) | Travel and Lodging | Cash or cash equivalent | $64.28 | General |
| Category: Infections and Infectious Diseases | ||||||
| 02/13/2019 | Shionogi Inc | Fetroja (Drug) | Travel and Lodging | Cash or cash equivalent | $22.00 | General |
| Category: Infections and Infectious Diseases | ||||||
| 02/13/2019 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | Cash or cash equivalent | $15.95 | General |
| Category: Infections and Infectious Diseases | ||||||
| 02/12/2019 | Shionogi Inc | Fetroja (Drug) | Travel and Lodging | Cash or cash equivalent | $406.59 | General |
| Category: Infections and Infectious Diseases | ||||||
| 02/12/2019 | Shionogi Inc | Fetroja (Drug) | Travel and Lodging | Cash or cash equivalent | $262.49 | General |
| Category: Infections and Infectious Diseases | ||||||
| 02/12/2019 | Shionogi Inc | Fetroja (Drug) | Travel and Lodging | Cash or cash equivalent | $150.05 | General |
| Category: Infections and Infectious Diseases | ||||||
| 02/12/2019 | Shionogi Inc | Fetroja (Drug) | Travel and Lodging | Cash or cash equivalent | $44.66 | General |
| Category: Infections and Infectious Diseases | ||||||
| 02/12/2019 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | Cash or cash equivalent | $15.39 | General |
| Category: Infections and Infectious Diseases | ||||||
| 10/03/2018 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $10,175.00 | General |
| 10/03/2018 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $147.30 | General |
| 10/03/2018 | GlaxoSmithKline, LLC. | — | Food and Beverage | Cash or cash equivalent | $50.23 | General |
| 10/03/2018 | GlaxoSmithKline, LLC. | — | Travel and Lodging | Cash or cash equivalent | $3.00 | General |
| 07/13/2018 | Janssen Products, LP | PREZCOBIX (Drug) | Education | In-kind items and services | $99.00 | General |
| Category: Infectious Diseases & Vaccines | ||||||
| 06/26/2018 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $588.35 | General |
| 06/26/2018 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $205.70 | General |
| 06/26/2018 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $114.79 | General |
| 06/26/2018 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $24.70 | General |
| 06/26/2018 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $17.18 | General |
| 06/26/2018 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $3.63 | General |
| 06/26/2018 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $3.36 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 34 | 40 | $4,670 | $2,647 |
| 2022 | 3 | 52 | 61 | $11,165 | $6,461 |
| 2021 | 5 | 102 | 123 | $18,687 | $11,447 |
| 2020 | 3 | 39 | 44 | $7,170 | $4,620 |
Total Patients
227
Total Services
268
Medicare Billing
$25,173
Procedure Codes
14
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 11 | 11 | $1,760 | $1,193 | 67.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 12 | 17 | $1,734 | $730.71 | 42.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 12 | $1,176 | $722.91 | 61.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 23 | 23 | $6,187 | $3,548 | 57.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 17 | 19 | $3,040 | $2,098 | 69.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 12 | 19 | $1,938 | $814.86 | 42.0% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 24 | 24 | $6,456 | $3,892 | 60.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 30 | 30 | $4,800 | $3,251 | 67.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 24 | 35 | $3,430 | $2,048 | 59.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 13 | 21 | $2,142 | $1,137 | 53.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 11 | 13 | $1,859 | $1,119 | 60.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 12 | 12 | $3,228 | $1,916 | 59.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 13 | 13 | $2,080 | $1,535 | 73.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 14 | 19 | $1,862 | $1,169 | 62.8% |
About Christopher Carpenter
Christopher Carpenter is a Infectious Disease healthcare provider based in Royal Oak, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1003875600.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Christopher Carpenter has received a total of $38,972 in payments from pharmaceutical and medical device companies, with $7,750 received in 2021. These payments were reported across 27 transactions from 4 companies. The most common payment nature is "Consulting Fee" ($36,505).
As a Medicare-enrolled provider, Carpenter has provided services to 227 Medicare beneficiaries, totaling 268 services with total Medicare billing of $25,173. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Royal Oak, MI
- Active Since 03/22/2006
- Last Updated 10/23/2020
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1003875600
Products in Payments
- Fetroja (Drug) $9,106
- SHINGRIX (Biological) $5,290
- PREZCOBIX (Drug) $198.99
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Royal Oak
Dr. Carmen Demarco, Md, MD
Infectious Disease — Payments: $687.12
Infectious Disease $687.12
John Szela, M.d, M.D
Infectious Disease — Payments: $339.74
Infectious Disease $339.74
Jeffrey Band
Infectious Disease — Payments: $10.89
Infectious Disease $10.89
Dr. Kamran Baig, Md, Mph, MD, MPH
Infectious Disease
Infectious Disease